Efficacy of the herbal preparation STW 5 in multi-target therapy of functional dyspepsia
Abstract
The aim of review. To discuss mechanisms of action and results of clinical application of plant-derived drug STW 5 (Iberogast®) for treatment of functional dyspepsia (FD).
Key points. Iberogast® is the combined agent containing extracts of 9 medicinal plants. Mechanism of action includes effect on motility of the stomach and intestine, visceral sensitivity along with anti-inflammatory and cytoprotective effects. Controlled clinical trials have confirmed high efficacy of Iberogast® at treatment of FD (including pediatric practice) as well as good tolerability of the drug.
Conclusion. Results of Iberogast® application allow to consider its as effective agent in multi-target therapy of FD.
About the Authors
A. A. Sheptulin
State educational government-financed institution of higher professional education «Sechenov First Moscow state medical university»
Russian Federation
Russian Federation
Sheptulin Arkady A. — MD, PhD, professor, chair of internal diseases propedeutics, medical faculty
119991, Moscow, Pogodinskaya street, 1, bld 1
V. O. Kaybysheva
State educational government-financed institution of higher professional education «Sechenov First Moscow state medical university»
Russian Federation
Russian Federation
Kaybysheva Valeriya O. — MD, assistant-professor, chair of internal diseases propedeutics, medical faculty
119991, Moscow, Pogodinskaya street, 1, bld 1
References
1. Ivashkin V.T., Sheptulin A.A., Lapina T.L., Kartavenko I.M., et al., Guidelines of the Russian gastroenterological association on diagnostics and treatment of functional dyspepsia. Ros zhurn gastroenterol gepatol koloproktol 2012; 22(3):80-92.
2. Kartavenko I.M. Morphofunctional assessment of duodenum at functional dyspepsia: Author's abstract. MD degree thesis. М., 2008. 23 p.
3. Allescher H.D. Functional dyspepsia – a multicausal disease and its therapy. Phytomedicine 2006; 13:2-11.
4. Allescher H.D., Wagner H. STW5/Iberogast: MultiTarget Wirkung bei funktioneller Dyspepsie und Reizdarmsyndrom. Wien Med Wochenschr 2007; 157: 301-7.
5. Ammon H.P.T., Kelber O., Okpanyi S.N. Spasmolytic and tonic effect of Iberogast (STW 5) in intestinal smooth muscle. Phytomedicine 2006; 13:67-74.
6. Braden B., Caspary W., Bὂrner N., et al. Clinical effects of STW 5 Iberogast are not based on acceleration of gastric emptying in patients with functional dyspepsia and gastroparesis. Neurogastroenterol Motil 2009; 21:632-9.
7. Buchert D. Wirksamkeit und Verträglichkeit von Iberogast bei Patienten mit gesicherter Non Ulkus Dyspepsie. Z Phytotherapie 1994; 15:45-6.
8. Caldarella M.P., Azpiroz F., Malagelada J.-R. Antrofundic dysfunction in functional dyspepsia. Gastroenterology 2003; 124:1202-29.
9. Callahan M.J. Irritable bowel syndrome neuropharmacology. A review of approved and investigational compounds. J Clin Gastroenterol 2002; 35 (Suppl.):58-67.
10. Germann I., Hagelauer D., Kelber O., et al. Antioxidative properties of the gastrointestinal phytopharmaceutical remedy STW 5 (Iberogast) and its components. Phytomedicine 2006; 13:36-44.
11. Gundermann K.-J., Godehardt E., Ulbrich M. Efficacy of a herbal preparation in patients with functional dyspepsia: a meta-analysis of double-blind, randomized clinical trials. Adv Ther 2003; 20:1-7.
12. Gundermann K.-J., Vinson B., Hänicke S. Die funktionelle Dyspepsie bei Kindern – eine retrospective Studie mit einem Phytopharmakon. Pädiatrie 2004; 10:1-6.
13. Hohenester B., Rűhl A., Kelber O., Schemann M. The herbal preparation STW5 (Iberogast) has potent and regionspecific effects on gastric motility. Neurogastroenterol Motil 2004; 16:765-73.
14. Holtmann G., Nandurkar S., Talley N.J., et al. Herbal medicine for the treatment of functional dyspepsia: a systematic review of the literature and meta-analysis. Gastroenterology 2007; 132(Suppl. 2): Abstract W1204.
15. Holtmann G., Talley N.J. Clinician’s manual on managing dyspepsia. Life Science Communications. London, 2000.
16. Jones M.P., Ebert Ch.C. Bloating and somatosensory amplification in functional dyspepsia (FD). Am J Gastroenterol 2003; 98:63-4.
17. Kamm M.A. The complexity of drug development for irritable bowel syndrome. Aliment Pharmacol Ther 2002; 16:343-51.
18. Keohane J., Quigley E.M.M. Functional dyspepsia: The role of visceral hypersensitivity in its pathogenesis. World J Gastoenterol 2006; 12:2672-6.
19. Khayyal M.T., El-Ghazaly M.A., Kenawy S., et al. Antiulcerogenic effect of some gastrointestinally acting plant extracts and their combination. Arzneim Forsch Drug Res 2001; 51:545-53.
20. Liu C., Kreis M., Glatze J., et al. The herbal preparation STW 5 (Iberogast) desensitizes intestinal afferents in the rat small intestine. Neurogastroenterol Motil 2004; 16:759-64.
21. Madisch A., Holtmann G., Plein K., Hotz J. Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial. Aliment Pharmacol Ther 2004; 19:271-9.
22. Madisch A., Melderis H., Mayr G., et al. Ein Phytotherapeutikum und seine modifizierte Rezeptur bei funktioneller Dyspepsie. Z Gastroenterologie 2001; 39:1-8.
23. Melzer J., Rὂsch W., Reichling J., et al. Meta-analysis: phytotherapy of functional dyspepsia with the herbal drug preparation STW 5 (Iberogast). Aliment Pharmacol Ther 2004; 20:1279-87.
24. Michael S., Abdel-Aziz H., Weiser D., et al. Adenosine A2A receptor contributes to the anti-inflammatory effect of the fixed herbal combination STW 5 (Iberogast) in rat small intestinal preparation. Naynun-Schmiedeberg’s Arch Pharmacol 2012; 385:411-21.
25. Ottilinger B., Storr M., Malfertheiner P., Allescher H.-D. STW 5 (Iberogast) - a safe and effective standart in the treatment of functional gastrointestinal disorders. Wien Med Wochenschr 2013; 163:65-72.
26. Pilichiewicz A.N., Horowitz M., Russo A., et al. Effects of Iberogast on proximal gastric volume, antropyloroduodenal motility and gastric emptying in healthy men. Am J Gastroenterol 2007; 102:1-8.
27. Raedsch R., Hanisch J., Bock P., et al. Wirksamkeit und Unbedenklichkeit des Phytopharmacons STW 5 versus Metoclopramid bei Funktioneller Dyspepsie unter Praxisbedingungen – eine retrolektive Kohortenstudie. Z Gastroenterol 2007; 45:1041-8.
28. Rὂsch W., Winson B., Sassin I. A randomized clinical trial comparing the efficacy of a herbal preparation SYW 5 with the prokinetic drug cisapride in patients with dysmotility type of functional dyspepsia. Z Gastroenterol 2002; 40:401-8.
29. Samson M., Verhagen M.A., van Berge-Henegouwen G.P., et al. Abnormal clearance of exogenous acid and increased acid sensitivity of the proximal duodenum in dyspeptic patients. Gastroenterology 1999; 116:515-20.
30. Schemann M., Michel K., Zeller F., et al. Regionspecific effects of STW 5 (Iberogast) and its components in gastric fundus, corpus and antrum. Phytomedicine 2006; 13:90-9.
31. Schempp H., Weiser D., Kelber O., Elstner E.F. Radical scavenging and anti-inflammatory properties of STW 5 (Iberogast) and its components. Phytomedicine 2006:45-50.
32. Simmen U., Kelber O., Okpanyi S.N., et al. Bimding of STW 5 (Iberogast) and its components to intestinal 5-HT, muscarinic M3, and opioid receptors. Phytomedicine 2006; 13:51-5.
33. Tack J., Talley N.J., Camilleri M., et al. Functional gastroduodenal disorders. Gastroenterology 2006; 130:1466-79.
34. Vinson B.R., Radke M. The herbal preparation STW 5 for the treatment of functional gastrointestinal diseases in children aged 3-14 years - a prospective non interventional study. Dig Dis Week Chicago 2011; Abstract #523.
35. Von Arnim U., Peitz U., Vinson B., et al. STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo-controlled double-blind study. Am J Gastroenterol 2007; 102:1268-75.
Review
For citations:
Sheptulin A.A., Kaybysheva V.O. Efficacy of the herbal preparation STW 5 in multi-target therapy of functional dyspepsia. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2015;25(5):101-106. (In Russ.)
Views:
259
Email this article 
